Navigation Links
Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease
Date:8/20/2009

FORT LAUDERDALE, Fla., Aug. 20 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Impax Pharmaceuticals, the brand division of Impax Laboratories, Inc., Hayward, CA, has selected the TrialMaster EDC solution for conducting a Phase III study in patients with Parkinson's Disease. "While managing a global multi site clinical trial there can be significant challenges in getting trial data when you want it and in the format that you need it," said Suneel Gupta, PhD, Chief Scientific Officer for Impax. "The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process. After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has enabled us to meet our very tight corporate timelines for this important study."

"We look forward to working with Impax to assist them in the fight to cure Parkinson's disease," remarked Stephen Johnson, COO of OmniComm Systems. "We are honored that after an extensive evaluation, OmniComm's electronic data capture solution, TrialMaster(TM), was chosen to capture and process their clinical trial data. TrialMaster(TM) will enable them to continue to make informed and strategic decisions that will be vital to their success as a company."

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through t
'/>"/>

SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
2. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
3. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
4. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
8. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
11. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Mich., Jan. 9, 2012  Diplomat Specialty Pharmacy, the nation,s ... today it has received limited distribution rights from ... On November 18, 2011, EYLEA ... Drug Administration and is indicated for the treatment ...
... Calif., Jan. 9, 2012 Uptake Medical ® ... C funding round. The round was led by Singapore-based ... Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and ... managing partner, will join the Uptake Medical board of ...
Cached Medicine Technology:Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection 2Uptake Medical Announces Successful Completion of Series C Financing 2
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 National Teen Driver ... of the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ... in encouraging parents of teen drivers to talk to their ... road. , Motor vehicle crashes are the leading cause of ... drivers involved in fatal crashes, and 859 (42%) of those ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 Houston ... to present the key elements of his innovative ... professor to plastic surgery residents and faculty at ... , where he, too, was once a medical student. ... the largest private cosmetic plastic surgery practices in Texas, ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... its leadership in the companion fields of stem cell research ... a new Stem Cell and Regenerative Medicine Center. ... (May 17) at a public lecture by famed developmental biologist ... the stage for a critical central entity under which the ...
... set a target of ten years for developing an AIDS ... ,"We have learned in that period of time how formidable ... president for research and development at the International AIDS Vaccine ... increased from $186 million in 1997 to $759 million in ...
... botched up surgeries generally suffer in silence, cough up more money ... mixed results. ,And here comes the news that a ... charging a flat fee that includes 90 days of follow-up treatment. ... come back to the hospital, it would not to send the ...
... effective in preventing vaginal and vulvar tumors, according to a ... Lancet, Dow Jones reports. ,Gardasil in clinical trials ... with strains 16 and 18, which together cause about 70% ... HPV strains 6 and 11, which together with HPV strains ...
... and Child Welfare, Dr. David Parirenyatwa, says that the ... severely compromised the country's health delivery system. ... Health Assembly in Geneva, Switzerland, to join the country ... He calls the sanctions an unacceptable and unjustified ...
... people who are affected by chronic back pain can ... discs , spinal stenosis, and complications from failed back ... chronic back pain is considered unsuitable due to its ... new study led by Dr. David Abejn investigates the ...
Cached Medicine News:Health News:UW Establishes Stem Cell and Regenerative Medicine Center 2Health News:AIDS Vaccine Still a Long Way Off 2Health News:US Hospital Group Offers Warranty on Surgeries 2Health News:US Hospital Group Offers Warranty on Surgeries 3Health News:Sanctions Imposed On Zimbabwe Can Threaten International Health Security 2
... The RX daytona is a fully automated ... in bench top analysers offering many features ... systems. With reusable glass cuvettes, on board ... reagents, the random access analyser can accommodate ...
Inquire...
... SelectSecure Lead System (Model 3830) is the ... lumenless design allows for flexibility and a ... insulation thickness. The SelectSecure lead system utilizes ... the lead in select locations in either ...
... protease secreted by the kidney, plays ... system. The renin-angiotensin system regulates blood ... retention by the kidney. Renin is ... including decreased intravascular volume and decreased ...
Medicine Products: